Modern Pulse Corticosteroid Therapy in Patients with Multiple Sclerosis: Adverse Events and Clinical and Pharmacological Measures to Eliminate Them
DOI:
https://doi.org/10.53933/sspmpm.v5i1.173Keywords:
multiple sclerosis, pulse therapy, corticosteroids, methylprednisolone, metacartin, steroid myopathy, side effectsAbstract
Pulse therapy with methylprednisolone remains the standard treatment for exacerbations of multiple sclerosis. The appointment of corticosteroids can cause several undesirable phenomena and complications, one of which is the development of steroid myopathy and pronounced general weakness. To reduce the expressiveness of these violations, metacartin was used. The study included 57 patients with a reliable diagnosis of multiple sclerosis at the stage of exacerbation of the pathological process. There were 32 (56.14%) patients with the relapsing-remitting course of multiple sclerosis, and 25 (43.85%) with the secondary-progressive course. All patients were randomly divided into two groups: I – 33 (80.83%) patients who underwent a course of pulse therapy with methylprednisolone followed by the introduction of metacartin, and II – 24 (19.17%) patients who received only pulse therapy with methylprednisolone therapy. Group I included 23 patients with relapsing-remitting course and 10 patients with secondary-progressive course multiple sclerosis. 15 patients with relapsing-remitting course and 9 patients with secondary-progressive course multiple sclerosis was included in the II group. The study showed the effectiveness of combination of pulse-therapy with methylprednisolone and the metacartin, the prescription of which reliably reduced the severity of "muscular" symptoms when pulse therapy was prescribed.
References
Olek M.J., Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. UpToDate. 30.04.2024. URL: https://www.uptodate.com/contents/treatment-of-acute-exacerbations-of-multiple-sclerosis-in-adults/print
Dargahi N., Katsara M., Tselios Т. et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain. Sci. 2017. Vol. 7. No.7. P.78. URL: https://doi.org/10.3390/brainsci7070078 DOI: https://doi.org/10.3390/brainsci7070078
Tobin О. Multiple sclerosis. Mayoclinic. 2024. URL: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274
Voloshyna N., Nehreba T., Kirzhner V., et al. Clinical and mathematical analysis of differences for various types of course in sporadic and familial forms of multiple sclerosis. International neurological journal. 2021. Vol.16. No.4. Р.26-32. DOI: https://doi.org/10.22141/2224-0713.16.4.2020.207347 DOI: https://doi.org/10.22141/2224-0713.16.4.2020.207347
Vasylovskyy V., Nehreba T., Voloshyna N. et al. Application of Glucocorticoids in Therapy of Multiple Sclerosis. SSP Modern Pharmacy and Medicine. 2024. Vol.4. No.2. Р.1-14. DOI: https://doi.org/10.53933/sspmpm.v4i2.141 DOI: https://doi.org/10.53933/sspmpm.v4i2.141
Voloshina N.P., Negreba T.V., Vasilovsky V.V. et al. Comparative effectiveness of hormonal pulse therapy in relapsing and secondary progressive types of multiple sclerosis with different prognosis (Communication II. Efficiency of hormonal pulse therapy at the onset and at the relapsing stage in relapsing and secondary progressive types of multiple sclerosis with different prognosis). International Neurological Journal. 2018. No. 7 (101). P. 11-16.URL: http://www.mif-ua.com/archive/article/46247
Yamout B. et al. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. 2020. Vol. 27. No 5. P. 755-766.
Thompson A.J. Multiple sclerosis. The Lancet. 2018. Vol.391. Is.10130. P.1622-1636. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30481-1/abstract DOI: https://doi.org/10.1016/S0140-6736(18)30481-1
Shapovalova V. The ICD-11 For the Twenty-First Century: The First View from The Organizational, Legal, Clinical and Pharmacological Aspects. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No 1. Р. 1-13. DOI: https://doi.org/10.53933/sspmpm.v2i1.37 DOI: https://doi.org/10.53933/sspmpm.v2i1.37
Ivanishyn-Hayduchok L., Shapovalova V., Shapovalov V. ICD-11: Organizational and Legal, Medical and Pharmaceutical, Social and Economic Issues of Implementation of the Program of State Guarantees of Medical Care in 2022 in Ukraine, Based on The Fundamental Principles of the European Union. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No 2. Р. 1-14. DOI: https://doi.org/10.53933/sspmpm.v2i2.53 DOI: https://doi.org/10.53933/sspmpm.v2i2.53
Voloshina N.P., Egorkina O.V. Strategies for the treatment of multiple sclerosis: efficacy and safety. Ukr. med. journal. 2012. No. 4. P. 32-37.URL: https://umj.com.ua/uk/publikatsia-38550-strategii-lecheniya-rasseyannogo-skleroza-effektivnost-i-bezopasnost
Shapovalova V. Multidisciplinary Case Studies of Neuro-Oncology Disorders: Administration, Clinical and Pharmacological, Organizational and Legal, Pharmaceutical Management. SSP Modern Pharmacy and Medicine. 2024. Vol.4. No.3. P.1-11. DOI: https://doi.org/10.53933/sspmpm.v4i3.151 DOI: https://doi.org/10.53933/sspmpm.v4i3.151
Shapovalov V., Shapovalova V., Osyntseva A., et al. Multidisciplinary context of research of a new drug in infectious and inflammatory diseases. Annals of Mechnikov’s Institute. 2024. No.3. Р.3–9. DOI: https://doi.org/10.5281/zenodo.13820208
Shapovalova V. Post-Traumatic Stress Disorder: Administration, Clinical and Pharmacological, Organizational and Legal, Pharmaceutical Management, Recent Case Studies. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No 1. Р. 1-8. DOI: https://doi.org/10.53933/sspmpm.v4i1.123 DOI: https://doi.org/10.53933/sspmpm.v4i1.123
Shapovalova V. Administration, Marketing, Pharmacotherapy of Medicines in Neuro-Oncology. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No 4. Р. 1-12. DOI: https://doi.org/10.53933/sspmpm.v4i4.161 DOI: https://doi.org/10.53933/sspmpm.v4i4.161
Shapovalova V.A., Shapovalov V.V. The clinical efficacy of the combined drug agent Valcophen in children. Likars'ka Sprava. 01 Jan 1999. No 1. Р. 124-126. URL: https://europepmc.org/article/med/10424023
Shapovalova V., Zbrozhek S., Shapovalov V. et al. Content analysis of pharmacies in Ukraine where extemporaneous medicines are manufactured. Health of Society. 2017. Vol. 6. No 3. Р. 77-83. DOI: https://doi.org/10.22141/2306-2436.6.3.2017.12349838 DOI: https://doi.org/10.22141/2306-2436.6.3.2017.123498
Shapovalova V. Innovative approaches to medical and pharmaceutical care, pharmacotherapy, and availability of pharmaceutical supplies for Tuberculosis patients in wartime. SSP Modern Pharmacy and Medicine. 2025. Vol.5. No.1. P.1-17. URL: https://doi.org/10.53933/sspmpm.v5i1.170 DOI: https://doi.org/10.53933/sspmpm.v5i1.170
Dubrov S.O., Negrych T.I., Voloshyna N.P. Evidence-based clinical guideline Multiple sclerosis in adults and children. State Enterprise "State Expert Center of the Ministry of Health of Ukraine". 2024. 310 p. URL: https://moz.gov.ua/uploads/ckeditor/%D0%93%D1%80%D0%BE%D0%BC%D0%B0%D0%B4%D1%81%D1%8C%D0%BA%D0%B5%20%D0%BE%D0%B1%D0%B3%D0%BE%D0%B2%D0%BE%D1%80%D0%B5%D0%BD%D0%BD%D1%8F/2024/02-2024/28-02-2024/2/024_02_09_%D0%9A%D0%9D_%D0%A0%D0%A1.pdf
Voloshin P.V., Linsky I.V., Maruta N.O. et al. Clinical recommendations for providing medical care to patients with neurological, mental and behavioral disorders. Kharkiv: Publisher Strokov D.V., 2021. 376 p. URL: https://cerebrolysin.com.ua/fileadmin/user_upload/materials/protocols/Clinical_guidelines-8-21.pdf
Shapovalova V.A., Sosin I.K., Butenko G.M. et al. Pharmaceutical law in narcology. Kharkov: “Fact”. 2004. 800 p.
Voloshina N.P., Vasylovsky V.V., Mikulinsky Yu.E. et al. Autotherapy with bone marrow stromal cells (MSCs) induced in the nerve in patients with chronic diseases of the CNS (multiple sclerosis, Parkinson's disease). Ukrainian Neurosurgical Journal. 2003. No. 3. P. 61-66. URL: https://theunj.org/article/view/107571/102525
Karussis D., Kassis I., Petrou P. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES. Multiple Sclerosis Journal. 2022. Vol. 28. Issue 9. P. 1324-1326. URL: https://pubmed.ncbi.nlm.nih.gov/35786042/ DOI: https://doi.org/10.1177/13524585211062173
Voloshyn P.V., Vorobyeva T.M., Voloshina N.P. Neurobiological mechanisms of therapeutic effects of distant transplantation of embryonic nerve tissues in modeling multiple sclerosis. Ukrainian Herald of Psychoneurology. 2005. Volume 13. Issue. 1 (42). P. 5-9.
Sharrack B., Hughes R.C., Morris R.W. et al. The effect of oral and intravenosus methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J. Neurol. Sci. 2000. Vol. 173. Issue 1. P. 73-77. URL: https://www.jns-journal.com/action/showCitFormats?doi=10.1016%2FS0022-510X%2899%2900304-4&pii=S0022-510X%2899%2900304-4 DOI: https://doi.org/10.1016/S0022-510X(99)00304-4
Cathcart E.S., Idelson B.A., Scheinberg M.A. et al. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. The Lancet. 1976. Vol.307. Iss.7952. Р.163-166. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(76)91272-1/fulltext. URL: https://pubmed.ncbi.nlm.nih.gov/54681/ DOI: https://doi.org/10.1016/S0140-6736(76)91272-1
Leussink V.I., Jung S., Merschdorf U. et al. Therapy in Multiple Sclerosis Induces Apoptosis in Peripheral Blood Leukocytes. Arch Neurol. 2001. Vol. 58. Issue 1. Р. 91-97. URL: https://jamanetwork.com/journals/jamaneurology/fullarticle/778382 DOI: https://doi.org/10.1001/archneur.58.1.91
Chernenko M.E. Albumin as an indicator of blood-brain barrier permeability in patients with multiple sclerosis. International Medical Journal. 2013. Vol. 19. No. 2 (74). P. 96-100.
Chernenko ME Matrix metalloproteinase-9 as an indicator of inflammatory process activity in patients with multiple sclerosis. Tavrichesky Journal of Psychiatry. 2012. Vol. 16. No. 4 (61). P. 96-100.
Negrich T.I,, Sorokin B.V. From generic diagnostics to effective therapy of multiple sclerosis. International Neurological Journal. 2012. No. 3. P. 152-158. URL: http://www.mif-ua.com/archive/article/29729
Schmidt J., Gold R., Schonroch L. et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain. 2000. Vol. 123. Iss.7. P.1431-1441. DOI: https://doi.org/10.1093/brain/123.7.1431 DOI: https://doi.org/10.1093/brain/123.7.1431
Liu S., Liu X., Chen S. et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS ONE. 2017. Vol.12. Iss.11. Р.e0188644. DOI: https://doi.org/10.1371/journal.pone.0188644 DOI: https://doi.org/10.1371/journal.pone.0188644
Pyndus V., Shapovalov V. Study of Pharmaceutical Provision Under the Program of Medical Guarantees in Ukraine. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No. 3. Р. 1-10. DOI: https://doi.org/10.53933/sspmpm.v4i3.155 DOI: https://doi.org/10.53933/sspmpm.v4i3.155
Osyntseva A. Forensic and evidence pharmacy: features of medical, pharmacological and pharmaceutical correction. Actual problem of medicine and pharmacy. 2020. Vol. 1 No. 1-2. URL: Retrieved from https://apmplmi.com/index.php/apmp/article/view/19
Filipovic S.R., Drulovic J., Stojsavljevic N. et al. The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J. Neurol Sci. 1997. Vol. 152. Issue 2. P. 147-153. URL: https://www.jns-journal.com/article/S0022-510X(97)00159-7/abstract DOI: https://doi.org/10.1016/S0022-510X(97)00159-7
Gold R., Buttgereit F., Toyka K.V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 2001. Vol. 117. Issue 1. P. 1-8. URL: https://www.jni-journal.com/article/S0165-5728(01)00330-7/abstract DOI: https://doi.org/10.1016/S0165-5728(01)00330-7
Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002. Vol.96. Iss.1. P.23-43. DOI: https://doi.org/10.1016/S0163-7258(02)00297-8 DOI: https://doi.org/10.1016/S0163-7258(02)00297-8
Huscher D., Thiele K., Gromnica-Ihle E. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 2009. Vol. 68. Iss.7. P.1119-1124. URL: https://ard.eular.org/article/S0003-4967(24)21712-X/fulltext DOI: https://doi.org/10.1136/ard.2008.092163
Shevchuk O.M. Itsenko-Cushing's disease: symptoms, causes and treatment. Pharmacy we wish you health. 06.11.2024. URL: https://apteka.net.ua/articles/khvoroba-itsenko-kushynha-symptomy-prychyny-i-likuvannya
Hoes J.N., van der Goes M.C., van Raalte D.H. et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann. Rheum. Dis. 2011. Vol.70. No.11. P.1887-94. URL: https://ard.eular.org/article/S0003-4967(24)19074-7/fulltext DOI: https://doi.org/10.1136/ard.2011.151464
Voloshina N.P., Vasilovsky V.V., Chernenko M.E. Influence of infectious factor on the state of the blood-brain barrier in patients with multiple sclerosis. Ukrainian Bulletin of Psychoneurology. 2013. Vol. 22. Issue. 1 (74). P. 5-6.URL: https://uvnpn.com.ua/
Piper J.M,. Ray W.A., Daugherty J.R. et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann. Intern. Med. 1991. Vol. 114. No 9. P. 735-775. DOI: https://doi.org/10.7326/0003-4819-114-9-735 DOI: https://doi.org/10.7326/0003-4819-114-9-735
Brown E.S., Chandler P.A. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J. Clin. Psychiatry. 2001 Feb. Vol. 3. No 1. P. 17-21. URL: https://www.psychiatrist.com/pcc/mood-cognitive-changes-during-systemic-corticosteroid/ DOI: https://doi.org/10.4088/PCC.v03n0104
Stuart F.A., Segal T.Y., Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch. Dis. Child. 2005 May. Vol. 90. Issue 5. P. 500-506. URL: https://adc.bmj.com/content/90/5/500 DOI: https://doi.org/10.1136/adc.2003.041541
Panoulas V.F., Douglas K.M., Stavropoulos-Kalinoglou A. et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008. Vol.47. Iss.1. P.72-77. DOI: https://doi.org/10.1093/rheumatology/kem311 DOI: https://doi.org/10.1093/rheumatology/kem311
Whitworth J.A. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987 May. Vol. 31. No 5. рр. 1213-1224. URL: https://pubmed.ncbi.nlm.nih.gov/3298796/ DOI: https://doi.org/10.1038/ki.1987.131
Hardman J.G. Limbird L.E., Gilman A.G. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. New York: Mcgraw-Hill (Tx); 9th edition. 1996. P. 1475. URL: https://www.amazon.com/Goodman-Gilmans-Pharmacological-Basis-Therapeutics/dp/0070262667
Shapovalova V. Extemporaneous preparations in the pharmacotherapy of nervous system disorders: pharmaceutical management, marketing, analysis, application. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.4. P.1-7. URL: https://doi.org/10.53933/sspmpm.v3i4.111 DOI: https://doi.org/10.53933/sspmpm.v3i4.111
Shapovalova V. Forensic and pharmaceutical risks in the organization of pharmacotherapy of covid, post-covid and long-covid disorders. COVID-19 and vaccination practice standards. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 4. P. 1–24. URL: https://doi.org/10.53933/sspmpm.v2i4.69. DOI: https://doi.org/10.53933/sspmpm.v2i4.69
Shapovalova V. Monkeypox virus – new challenges of modernity: experimental organizational and legal, clinical and pharmacological studies. SSP Modern Pharmacy and Medicine. 2022. Vol.2. N.3. P.1-15. URL: https://doi.org/10.53933/sspmpm.v2i3.54. DOI: https://doi.org/10.53933/sspmpm.v2i3.54
Shapovalova V. Pharmacotherapy of Depressive disorders in conditions of coronavirus disease: pharmacoeconomic experimental study. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.3. P.1-11. URL: https://doi.org/10.53933/sspmpm.v3i3.101 DOI: https://doi.org/10.53933/sspmpm.v3i3.101
Chernenko M. E. The problem of neurogenesis in the context of therapy of neuroinflammatory/neurodegenerative processes. International Medical Journal. 2019. Vol. 25. No. 2 (98). P. 53-56.
Dalakas M.C. Current treatment of the inflammatory myopathies. Curr. Opin. Rheumatol. 1994. Vol.6. No.6. P.595-601. URL: https://journals.lww.com/co-rheumatology/abstract/1994/11000/current_treatment_of_the_inflammatory_myopathies.8.aspx DOI: https://doi.org/10.1097/00002281-199411000-00008
McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals. of neurology. 2001. Vol.50. No.1. Р.121-128. DOI: https://doi.org/10.1002/ana.20703 DOI: https://doi.org/10.1002/ana.20703
Wexler M. Guidelines for MS diagnosis: McDonald criteria. Multiple Sclerosis News Today. 13.04.2023. URL: https://multiplesclerosisnewstoday.com/ms-diagnosis-mcdonald-criteria/
Expanded Disability Status Scale (EDSS). MS Trust. 14.10.2024. URL: https://mstrust.org.uk/a-z/expanded-disability-status-scale-edss
Patzold T., Schwengelbeck M., Ossege L.M. et al. Changes of the MS Functional Composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol. Scand. 2002. Vol. 105. No 3. P. 164-172. DOI: https://doi.org/10.1034/j.1600-0404.2002.1o135.x DOI: https://doi.org/10.1034/j.1600-0404.2002.1o135.x
Arsoy E., Bulut N., Pamuk S. et al. The Multiple Sclerosis Functional Composite (MSFC) for Determining Disease Progression: A Methodological Study. J. Mult. Scler. Res. 2022. Vol.2. Iss.1. P. 5-12. URL: https://jmsres.com/jvi.aspx?pdir=jmsres&plng=eng&un=JMSRES-60352&look4= DOI: https://doi.org/10.4274/jmsr.galenos.2022.2022-3-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maksym Chernenko, Tetiana Nehreba, Nataliya Voloshyna, Vitaliy Vasylovskyy; Tetiana Pohulaieva
This work is licensed under a Creative Commons Attribution 4.0 International License.
